[go: up one dir, main page]

AR031316A1 - Compuestos antitumorales activados por fap ii - Google Patents

Compuestos antitumorales activados por fap ii

Info

Publication number
AR031316A1
AR031316A1 ARP010105240A ARP010105240A AR031316A1 AR 031316 A1 AR031316 A1 AR 031316A1 AR P010105240 A ARP010105240 A AR P010105240A AR P010105240 A ARP010105240 A AR P010105240A AR 031316 A1 AR031316 A1 AR 031316A1
Authority
AR
Argentina
Prior art keywords
fapalfa
fap
prodrug
physiological conditions
under physiological
Prior art date
Application number
ARP010105240A
Other languages
English (en)
Spanish (es)
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of AR031316A1 publication Critical patent/AR031316A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06017Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1019Tetrapeptides with the first amino acid being basic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1024Tetrapeptides with the first amino acid being heterocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP010105240A 2000-11-10 2001-11-09 Compuestos antitumorales activados por fap ii AR031316A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0027552.9A GB0027552D0 (en) 2000-11-10 2000-11-10 Anti-tumor compounds

Publications (1)

Publication Number Publication Date
AR031316A1 true AR031316A1 (es) 2003-09-17

Family

ID=9902983

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010105240A AR031316A1 (es) 2000-11-10 2001-11-09 Compuestos antitumorales activados por fap ii

Country Status (5)

Country Link
AR (1) AR031316A1 (fr)
AU (1) AU2002220684A1 (fr)
GB (1) GB0027552D0 (fr)
UY (1) UY27014A1 (fr)
WO (1) WO2002038590A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1963537A4 (fr) * 2005-12-14 2009-11-11 Ludwig Inst For Cancer Res Ltd Procede permettant de diagnostiquer une arthrite rhumatoide par le dosage des synoviocytes de type fibroblastique pour la proteine d'activation des fibroblastes
DK2525830T3 (en) 2010-01-22 2016-08-15 Ascendis Pharma As DIPEPTID-BASED PRODRUG LINKERS TO ALIFATIC AMINE-CONTAINING MEDICINES
US20130030359A1 (en) 2010-01-22 2013-01-31 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aromatic amine-containing drugs
AU2013369261B2 (en) 2012-12-28 2018-08-09 Cobiores Nv Minimally toxic prodrugs
HUE063194T2 (hu) * 2014-06-13 2024-01-28 Bach Biosciences Llc FAP-aktivált terápiás szerek és az azokkal kapcsolatos felhasználások
US9737556B2 (en) 2014-06-13 2017-08-22 Trustees Of Tufts College FAP-activated therapeutic agents, and uses related thereto
EP3565560B1 (fr) 2017-01-09 2024-05-29 OnkosXcel Therapeutics, LLC Procédés prédictifs et diagnostiques pour le cancer de la prostate
EP4267188A1 (fr) 2020-12-22 2023-11-01 Cobiores NV Composés comprenant une fraction tétrapeptidique
WO2022167664A1 (fr) 2021-02-07 2022-08-11 Cobiores Nv Composés comprenant une fraction tétrapeptidique
CN120590466A (zh) * 2025-08-06 2025-09-05 首都医科大学脑重大疾病研究中心(北京脑重大疾病研究院) 一种靶向成纤维细胞活化蛋白的化合物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
EP0855910A4 (fr) * 1995-10-18 2000-07-05 Merck & Co Inc Conjugues utiles pour traiter l'adenome prostatique benin
US6613879B1 (en) * 1999-05-14 2003-09-02 Boehringer Ingelheim Pharma Kg FAP-activated anti-tumour compounds

Also Published As

Publication number Publication date
WO2002038590A1 (fr) 2002-05-16
AU2002220684A1 (en) 2002-05-21
UY27014A1 (es) 2002-07-31
GB0027552D0 (en) 2000-12-27

Similar Documents

Publication Publication Date Title
AR033792A1 (es) Compuestos anti - tumorales activados por paf
HN1999000124A (es) Derivados de pirazol substituido.
DE602006014990D1 (de) Intranasale verabreichung von schnell wirkendem insulin
HN2003000196A (es) Derivados de indolinfenilsulfonamida
CR7171A (es) Composiciones farmaceuticas de farmacos y polimeros acidos neutralizados
AR031316A1 (es) Compuestos antitumorales activados por fap ii
ES2267706T3 (es) Agentes como la nicotinamida o cardr para el tratamiento de trastornos de la piel.
BRPI0516830A (pt) composições de droga de liberação sustentada convenientemente implantáveis
UY27939A1 (es) Compuestos
BRPI0411900B8 (pt) compostos e composições farmacêuticas compreendendo os mesmos
ES2067696T3 (es) Composiciones de liberacion sostenida para tratar la enfermedad periodontal.
CR10838A (es) Derivados de 2,3-dihidroimidazol [1,2-c] quinazolina sustituidos, de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis
ECSP034567A (es) Inhibidores de espiropirimidin-2,4,6-triona metaloproteinasas
PT1411938E (pt) Utilizacao da ciclopamina para a preparacao de um medicamento para o tratamento de psoriase
ECSP045353A (es) Derivados de benzoxazinona, su preparación y aplicación como medicamentos
HN2000000045A (es) Nuevas combinaciones farmaceuticas para inhibidores de la nos.
ES2177849T3 (es) Preparado farmaceutico, que contiene 2-fenil-1,2-benzoisoselenazol-3(2h)-ona, para el tratamiento de la enfermedad de alzheimer.
HN2003000015A (es) Sales estables del acido o acetilsalicilico con aminoacidos basicos i i.
PT1331940E (pt) Utilizacao da pentraxina longa ptx3 para o tratamento de doencas provocadas por uma activacao alterada do factor de crescimento fgf-2
PA8661701A1 (es) Tiazolidinonas, su preparacion y su uso como medicamento
HN2001000204A (es) Amidas de acido fenilciclohexanocarboxilico sustituido y su uso
HN2000000078A (es) Amidas sustituidas del acido fenilciclohexanocarboxilico y su uso como inhibidores de la incorporacion de adenosina
HN2000000072A (es) Amidas de acidos fenilciclohexanocarboxilicos sustituidos
SV2002000639A (es) Alcanosulfonatos de fenoxifenilo ref. lea 34813-sv
ES2140329A1 (es) Utilizacion de acido maslinico como inhibidor de proteasas para el tratamiento de la enfermedad causada por los virus de la inmunodeficiencia adquirida.

Legal Events

Date Code Title Description
FB Suspension of granting procedure